Pandemic Perspectives: 20-Plus Vaccines In Development As India Tackles COVID-19 Surge
Will Exports Resume In August?
From mRNA to subunit vaccines, Indian companies have 20 COVID-19 vaccine candidates, while three have already been approved. An August nod for Biological E could not just cut down time to immunize the country's population but also allow exports to resume.
You may also be interested in...
Japan has granted an emergency approval to Chugai/Roche/Regeneron's antibody cocktail after a rapid review, while India has emerged as one of the top purchasers globally of COVID-19 vaccines as it looks to protect more of its population.
A plasmid DNA vaccine for human use has moved a step closer to reality, with Zydus Cadila applying for an accelerated nod for its COVID-19 candidate in India. 67% efficacy reported in an interim data readout and Delta variant being the prominent strain during a Phase III trial imply better odds for approval.
Cipla is no novice in the vaccines segment and a potential link up for Moderna’s mRNA COVID-19 vaccine or with other firms could add an important lever in the 80-plus year-old Indian firm’s overall strategic thrust. Management has all along maintained a positive tone for coronavirus vaccine alliances.